If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
CyberKnife Centers Are Meeting Increasing Demand for Radiosurgery Using Sophisticated Treatment Planning and Delivery Technologies SUNNYVALE, Calif., May 22 (HSMN NewsFeed) — Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radio…
Devices, Oncology
Accuray, CyberKnife, radiosurgery
Posts from ‘May, 2009’
Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife
Johnson and Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 (HSMN NewsFeed) — Johnson & Johnson (NYSE: JNJ ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB ), a developmen…
Biopharmaceuticals, Oncology, Mergers & Acquisitions
Johnson & Johnson, Cougar Biotechnology
AMG International Announces the European Regulatory Submission of its Next Generation of Coronary Drug Stents’Itrix’ at European PCR Congress in Barcelona, Spain
German Laboratory Device Manufacturer AMG International GmbH announced the submission of its proprietary Itrix Stent Technology using its patented biodegradable drug coating. BARCELONA, Spain, May 21 (HSMN NewsFeed) — Three years after the first introdu…
Device,s Interventional Cardiology
AMG International, Itrix stent, Rapamycin, drug eluting stent
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Once-Daily SAMSCA Increases Serum Sodium Levels Through Increase in Free Water Clearance TOKYO and PRINCETON, N.J., May Twenty one (HSMN NewsFeed) — Otsuka Clinical Co., Ltd. (OPC) and Otsuka Clinical Development and Commercialization, Inc. (OPDC…
Biopharmaceuticals, FDA
Otsuka Medical, SAMSCA, tolvaptan
Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD
LUTON, England, May 21 (HSMN NewsFeed) — Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease (COPD) show that budesonide/formoterol (Symbicort®: AstraZeneca) plus tiotr…
Biopharmaceuticals
AstraZeneca, budesonide/formoterol, Symbicort
Clovis Oncology Raises $145 Million in Start-Up Financing
New company founded by members of former Pharmion executive team Company focused on acquiring, developing and marketing innovative anti-cancer compounds BOULDER, Colo., May 21 (HSMN NewsFeed) — Clovis Oncology, Inc., a company focused on acquiring…
Biopharmaceuticals, Oncology, Venture Capital
Clovis Oncology
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
NEW YORK, May 20 (HSMN NewsFeed) — Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX ) announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company. It’s also anticipated that Ron Bentsur will join the C…
Biopharmaceuticals, Personnel
Keryx Biopharmaceuticals
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
NATICK, Mass., May Twenty (HSMN NewsFeed) — Boston Scientific Corporation (NYSE: BSX ) today announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company’s EPIC(TM) Self-Expanding Nitinol Stent System for …
Devices, Interventional
Boston Scientific, Nitinol Stent, EPIC Stent, ORION trial
Smith and Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair
System Can Also Be Used For Mini-Open And Open Surgeries ANDOVER, Mass., May 20 (HSMN NewsFeed) — Smith & Nephew’s (NYSE: SNN ; LSE: SN ) Endoscopy Division today announced the launch of the BICEPTOR Tenodesis (TEEN-oh-DEE-sis) System to treat injuri…
Devices, Orthopaedic
Smith & Nephew, BICEPTOR Tenodesis, tenodesis procedure
Pfizer Expands Its Generics Portfolio Through Innovative Licensing Deals, Increasing Access To Medicines For Billions Worldwide
60 Products will be available in more than 70 countries throughout Asia, Latin America, Africa and the Middle East More than 100 Products will be available across North America, Europe, Australia, New Zealand NEW YORK–(HSMN NewsFeed)–Pfizer Inc an…
Biopharmaceuticals, Generics, Licensing
Pfizer, Aurobindo Pharma, Claris Lifesciences
